Zurich consensus: German expert opinion on the St. Gallen votes on 15 march 2009 (11th international conference at St. Gallen: Primary therapy of early breast cancer)

Breast Care

Volumn 4, Issue 2, 2009, Pages 109-116

  Beckmann, Matthias W ^a   Blohmer, Jens Uwe ^b   Costa, Serban Dan ^c   Diedrich, Klaus ^c   Diel, Ingo ^d   Eiermann, Wolfgang ^e,u   Friese, Klaus ^f   Gerber, Bernd ^g   Harbeck, Nadia ^h   Hilfrich, Joern ⁱ   Janni, Wolfgang ^c   Jaenicke, Fritz ^j   Jonat, Walter ^c   Kaufmann, Manfred ^k   Kiechle, Marion ^l   Koehler, Uwe ^m   Kreienberg, Rolf ⁿ   Von Minckwitz, Gunter ^o   Moebus, Volker ^p   Nitz, Ulrike ^q   Schneeweiss, Andreas ^r   Thomssen, Christoph ^s   Wallwiener, Diethelm ^t   more..

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b St Gertrauden Hospital   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Gynecology and Obstetrics Joint Practice   (Germany)

^e Red Cross Hospital   (Germany)

^f Munich University Women's Hospital   (Germany)

^g Rostock University Women's Hospital   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ Eilenriede Clinic Hannover   (Germany)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^k UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^l TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^m Klinikum St Georg   (Germany)

ⁿ UNIVERSITY HOSPITAL ULM   (Germany)

^o German Breast Group   (Germany)

^p SANOFI   (France)

^q Bethesda Hospital   (Germany)

^r UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^s MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^t UNIVERSITY OF TÜBINGEN   (Germany)

^u Frauenklinik vom Roten Kreuz   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN; GRANULOCYTE COLONY STIMULATING FACTOR; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; ZOLEDRONIC ACID;

ADD ON THERAPY; ADJUVANT THERAPY; BREAST CANCER; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; GENE OVEREXPRESSION; GENETIC ANALYSIS; GERMANY; HIGH RISK PATIENT; HUMAN; LIFESTYLE; MASTECTOMY; MEDICAL EXPERT; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRACTICE GUIDELINE; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; TREATMENT DURATION;

EID: 67649221359     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000212164     Document Type: Conference Paper

References (0)